title: The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis.
abstract: BACKGROUND
  Robenacoxib is a novel and highly selective inhibitor of COX-2 in dogs and cats and because of its acidic nature is regarded as being tissue-selective. Thirty four dogs with stifle osteoarthritis secondary to failure of the cranial cruciate ligament were recruited into this study. Lameness, radiographic features, synovial cytology and C-reactive protein concentrations in serum and synovial fluid were assessed before and 28 days after commencing a course of Robenacoxib at a dose of 1 mg/kg SID.
  
  
  RESULTS
  There was a significant reduction in the lameness score (P < 0.01) and an increase in the radiographic score (P < 0.05) between pre- and post-treatment assessments. There was no difference between pre- (median 1.49 mg/l; Q1-Q3 0.56-4.24 mg/L) and post - (1.10 mg/L; 0.31-1.78 mg/L) treatment serum C-reactive protein levels although synovial fluid levels were significantly reduced (pre- : 0.44 mg/L; 0.23-1.62 mg/L; post- : 0.17 mg/L; 0.05-0.49 mg/L) (P < 0.05). There was no correlation between C-reactive protein concentrations in serum and matched synovial fluid samples.
  
  
  CONCLUSIONS
  Robenacoxib proved effective in reducing lameness in dogs with failure of the cranial cruciate ligament and osteoarthritis of the stifle joint. The drug also reduced levels of C-reactive protein in the synovial fluid taken from the affected stifle joint. Robenacoxib appears to reduce articular inflammation as assessed by C-reactive protein which supports the concept that Robenacoxib is a tissue-selective non-steroidal anti-inflammatory drug.
authors: School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH, Scotland. David.Bennett@glasgow.ac.uk
authors: David
authors: D
authors: Bennett
authors: Peter David
authors: PD
authors: Eckersall
authors: Mary
authors: M
authors: Waterston
authors: Veronica
authors: V
authors: Marchetti
authors: Alessandra
authors: A
authors: Rota
authors: Eilidh
authors: E
authors: McCulloch
authors: Silvia
authors: S
authors: Sbrana
mesh_terms: D000818:Animals; D002097:C-Reactive Protein / Q000032:analysis*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004159:Diphenylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D007794:Lameness, Animal / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology; D008297:Male; D010003:Osteoarthritis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary*; D010648:Phenylacetates / Q000627:therapeutic use*; D011859:Radiography; D013264:Stifle / Q000000981:diagnostic imaging; D013582:Synovial Fluid / Q000737:chemistry* / Q000187:drug effects
chemical_list: D016861:Cyclooxygenase Inhibitors; D010648:Phenylacetates; D002097:C-Reactive Protein; D004159:Diphenylamine; C551524:robenacoxib